The first of such dual-agonist, MAR709, shows nearly balanced activity at both target receptors and improves body weight and glycemia with greater potency relative to pharmacokinetically-matched GLP-1 in rodents with diet- and genetically induced obesity (126). The gene discussed is GCG; the disease is obesity disorder.